Genetic Signatures secures major European growth milestone. The ASX-listed biotech company has signed a 10-year supply agreement with Denmark's Hvidovre Hospital for its EasyScreen Pan-Enteric gastrointestinal screening technology. Commercial orders begin September 2026, with first-year volumes projected at 28,000 samples and three percent annual growth. This long-term contract strengthens the company's EMEA expansion strategy and establishes recurring revenue streams from equipment, reagents, and consumables. The deal arrives as Genetic Signatures implements cost-reduction measures targeting up to five million dollars in annual savings from FY2027, following recent restructuring that includes redundancies and outsourced product development. The company reported stable half-year revenue of 8.
Post from MarketNews_en
Log in to interact with content.